

AMENDMENTS TO THE CLAIMS

Claims 1-20: (Canceled.)

21. (Currently Amended) A method of suppressing a rejection to a minor antigen in an corneal epithelium allograft in a subject in need thereof, comprising administering to recipient of said corneal epithelium allograft an effective amount of a composition comprising a substance having a function of decreasing a reduced glutathione content in at least one cell selected from the group consisting of macrophages, monocytes and dendric cells, and thereby the rejection to a minor antigen in said corneal epithelium allograft is suppressed,

wherein the substance is at least one member selected from the group consisting of a N, N'-diacylcystine, N, N'-diacylcystine ester, L-S, R-buthionine sulfoximine, R-buthionine sulfoximine derivative and a maleic acid diester.

22. (Previously Presented) The method according to claim 21, wherein the substance can reduce the glutathione content by at least 30% when incubated in vitro with macrophages for from 1 to 24 hours.

23. (Previously Presented) The method according to claim 21, wherein the substance has the function of decreasing a reduced glutathione content in macrophages.

24. (Withdrawn) The method according to claim 21, wherein the substance has the function of decreasing a reduced glutathione content in monocytes.

25. (Withdrawn) The method according to claim 21, wherein the substance has the function of decreasing a reduced glutathione content in dendric cells.

26. (Previously Presented) The method according to claim 21, wherein the substance is a N, N'-diacylcystine ester.

27. (Previously Presented) The method according to claim 21, wherein the substance is a N, N'-diacylcystine.

28. (Currently Amended) The method according to claim 21, wherein the corneal epithelium allograft is an allograft of the whole corneal epithelium at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

29. (Currently Amended) The method according to claim 21, wherein the corneal epithelium allograft is an allograft of a part of at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and the corneal epithelium.

30. – 32. (Canceled)

33. (Previously Presented) The method according to claim 21, wherein the composition is in the form of an oral drug, eye drop or infusion.

34. (Currently Amended) The method according to claim 21, wherein the recipient of said corneal epithelium allograft is a mammal.

35. (Currently Amended) The method according to claim 21, wherein the recipient of said corneal epithelium allograft is a human.

36. (Previously Presented) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of an oral drug, eye drop and infusion.

37. (Previously Presented) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of a pharmaceutical, food, drink and nutriment.

38. (Previously Presented) The method according to claim 21, wherein the composition is administered at a dose ranging from at least once a day to at least once every 5 days.

39. (Previously Presented) The method according to claim 21, wherein the composition is administered at a dose ranging from 1 mg to 10 g.

40. (Previously Presented) The method according to claim 21, wherein the substance is a L-S, R-buthionine sulfoximine.

41. (Previously Presented) The method according to claim 21, wherein the substance is a R-buthionine sulfoximine derivative.

42. (Previously Presented) The method according to claim 21, wherein the substance is a maleic acid diester.

43. (New) The method according to claim 21, wherein the substance is administered in as an eye drop.

SUPPORT FOR THE AMENDMENTS

Claims 1-20 and 32 were previously canceled.

Claim 30-31 is presently canceled.

Claims 21, 28, 29, 34, and 35 have been amended.

Claim 43 has been added.

Support for the amendment of Claims 21, 28, 29, 34, and 35 and the addition of new Claim 43 can be found in the specification as filed, for example at pages 5-47. Additional support for the amendment of Claims 21, 28, 29, 34, and 35 and the addition of new Claim 43 can be found in originally filed Claims 1-20 (see, for example, Claims 5, 6, 8, and 10).

No new matter has been added by the present amendments.